ADIL · Adial Pharmaceuticals, Inc.
$3.29
+0.14 (+4.44%)
At close · Jul 30
Going-concern doubt
— flagged May 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company does not believe that the existing cash and cash equivalents are sufficient to fund operations for the next twelve months following the filing of these unaudited condensed financial statements. During 2026, the Company received net proceeds of approximately $0.3 million from equity issuances. However, the Company will require additional capital to continue operations and development of AD04. These factors raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 8, 2026
Market Cap
$7.05M
Shares
2.14M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-07-13 | 1,551 | $2.78 | $4,312 |
| 2026-07-10 | 924 | $2.80 | $2,587 |
| 2026-07-07 | 27 | $2.90 | $78 |
| 2026-07-06 | 500 | $2.90 | $1,450 |
| 2026-07-02 | 2,420 | $2.81 | $6,800 |
| 2026-07-01 | 105 | $2.56 | $269 |
| 2026-06-30 | 41 | $2.59 | $106 |
| 2026-06-26 | 1,910 | $2.58 | $4,928 |
| 2026-06-25 | 38,263 | $2.48 | $94,892 |
| 2026-06-24 | 2,128 | $2.55 | $5,426 |
| 2026-06-23 | 10,913 | $2.71 | $29,574 |
| 2026-06-22 | 10,533 | $2.60 | $27,386 |
| 2026-06-18 | 33,835 | $2.75 | $93,046 |
| 2026-06-17 | 6,128 | $2.54 | $15,565 |
| 2026-06-16 | 8,304 | $2.85 | $23,666 |
| 2026-06-15 | 13,326 | $2.98 | $39,711 |
| 2026-06-12 | 135,815 | $2.98 | $404,729 |
| 2026-06-11 | 10 | $2.16 | $22 |
| 2026-06-09 | 81 | $2.21 | $179 |
| 2026-05-29 | 6,512 | $2.53 | $16,475 |
| 2026-05-27 | 2,239 | $2.24 | $5,015 |
| 2026-05-22 | 4,512 | $2.30 | $10,378 |
| 2026-05-19 | 3,794 | $1.61 | $6,108 |
| 2026-05-15 | 40 | $1.36 | $54 |
Showing 1–24 of 24 settlements
Key facts
CIK
1513525
CUSIP
00688A304
13F (30d)
30 filings
5 filers
Visit website
Investor relations